

I am writing this email in support of the placement of Invokana on a favorable status on the Medicaid PDL. I feel this innovative class of oral diabetic medication has been a great asset to the treatment of type 2 diabetes. The efficacy and tolerability with this class has been equal to or superior to comparable oral hypoglycemics. A significant benefit with Invokana is the recent study published in the New England Journal of medicine which reveals that patients treated with Invokana had a lower risk of cardiovascular events than those receiving placebo. As you well know, cardiovascular disease is a leading cause of death for patients with diabetes. I feel a treatment that decreases the risk for cardiovascular events is a true asset to diabetes treatment.